Advanced imaging techniques for brain tumor surgery
Multimodal Image-guided Resection of IDH Wildtype Glioblastoma and Grade IV IDH-mutant Astrocytoma
This study is testing if advanced imaging techniques can help doctors remove brain tumors more accurately in patients with certain types of glioblastoma to improve their outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Amsterdam, North Holland) |
| Trial ID | NCT06623565 on ClinicalTrials.gov |
What this trial studies
This study focuses on improving surgical outcomes for patients with IDH-wildtype glioblastoma and grade IV IDH-mutant astrocytoma by utilizing advanced imaging techniques. It aims to identify tumor regions with lower infiltration using a combination of apparent diffusion coefficient MRI and O-(2-[18F]fluoroethyl-)-L-tyrosine PET, which is believed to be more accurate than traditional MRI methods. The goal is to guide a more precise supramarginal resection during surgery, potentially leading to better patient prognoses. The study involves patients who are eligible for surgical resection and have visible FET PET uptake in their tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with newly diagnosed IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma who are eligible for surgical resection.
Not a fit: Patients with previous brain surgery, cranial radiotherapy, or other significant brain pathologies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve surgical outcomes and survival rates for patients with aggressive brain tumors.
How similar studies have performed: While the use of advanced imaging techniques in brain tumor surgery is gaining traction, this specific combination of imaging modalities for guiding supramarginal resection is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma * Visible FET PET uptake in the tumor as assessed by the nuclear physician * Indication for a surgical resection and adjuvant treatment according to the neuro oncology multidisciplinary meeting * Eligible for a supramarginal resection according to two neurosurgeons in consensus * Karnofsky Performance Score (KPS) ≥ 70. Exclusion Criteria: * Previous brain surgery or cranial radiotherapy * No significant other brain pathology, in the opinion of the PI or designee, such as multiple sclerosis, neurodegenerative disease, stroke * Tumor located infratentorially or in the spinal cord * Lack of adequate social or family support needed for adherence to the further postoperative therapeutic regimen * Pregnancy
Where this trial is running
Amsterdam, North Holland
- Amsterdam UMC location VUmc — Amsterdam, North Holland, Netherlands (Recruiting)
Study contacts
- Study coordinator: Niels Verburg, MD PhD
- Email: n.verburg@amsterdamumc.nl
- Phone: +31204445013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.